„Iron Heart”: Reversible Cause of Dilated Cardiomyopathy Secondary to Cardiac Toxicity in Elderly Patient with Myelodysplastic Syndrome Case report
##plugins.themes.bootstrap3.article.main##
Abstrakt
The most common non-hematological cause of death in patients with low-risk myelodysplastic syndrome (MDS) who receive chronic supportive transfusion therapy (STT) through red blood cells (RBC) is known to be related to cardiac events, especially, cardiac siderosis [1].
At the time patients develop symptoms secondary to cardiac toxicity, the disease reaches an advanced phase with a very high mortality rate. However, we report the case of an old female patient with severe acute heart failure (HF) and signs of elevated myocardial iron deposits by cardiac magnetic resonance, who experienced an unexpected and marked clinical improvement using a combination of intensive iron chelation therapy (ICT) and specific treatment for HF. She overcame the HF acute phase, recovered her systolic function and remained stable at mid-term of follow-up (18 months).
Pobrania
##plugins.generic.paperbuzz.metrics##
##plugins.themes.bootstrap3.article.details##
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
2. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010; 56: 1001-12.
3. Remacha AF, Arrizabalaga B, Villegas A et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol 2015; 94: 779-87.
4. Modell B, Khan M, Darlison M et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10: 42.
5. Tanner MA, He T, Westwood MA et al. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006; 91: 1388-91.
6. Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011; 2011: 443-50.